Literature DB >> 31582633

Non-naturally Occurring Helical Molecules Can Interfere with p53-MDM2 and p53-MDMX Protein-Protein Interactions.

Aoze Su1, Siyuan Wang1, Akane Sada2, Yuko Otani1, Luhan Zhai1, Xin Liu1, Misa Sayama1, Rieko Ohki2, Tomohiko Ohwada1.   

Abstract

We have discovered that β-amino acid homooligomers with cis- or trans-amide conformation can fold themselves into highly ordered helices. Moreover, unlike α-amino acid peptides, which are significantly stabilized by intramolecular hydrogen bonding, these helical structures are autogenous conformations that are stable without the aid of hydrogen bonding and irrespective of solvent (protic/aprotic/halogenated) or temperature. A structural overlap comparison of helical cis/trans bicyclic β-proline homooligomers with typical α-helix structure of α-amino acid peptides reveals clear differences of pitch and diameter per turn. Bridgehead substituents of the present homooligomers point outwards from the helical surface. We were interested to know whether such non-naturally occurring divergent helical molecules could mimic α-helix structures. In this study, we show that bicyclic β-proline oligomer derivatives inhibit p53-MDM2 and p53-MDMX protein-protein interactions, exhibiting MDM2-antagonistic and MDMX-antagonistic activities.

Entities:  

Keywords:  helix; p53–MDM2 interaction; p53–MDMX interaction; protein–protein interaction; β-proline

Mesh:

Substances:

Year:  2019        PMID: 31582633     DOI: 10.1248/cpb.c19-00501

Source DB:  PubMed          Journal:  Chem Pharm Bull (Tokyo)        ISSN: 0009-2363            Impact factor:   1.645


  3 in total

Review 1.  Therapeutic opportunities in cancer therapy: targeting the p53-MDM2/MDMX interactions.

Authors:  Murali Munisamy; Nayonika Mukherjee; Levin Thomas; Amy Trinh Pham; Arash Shakeri; Yusheng Zhao; Jill Kolesar; Praveen P N Rao; Vivek M Rangnekar; Mahadev Rao
Journal:  Am J Cancer Res       Date:  2021-12-15       Impact factor: 6.166

Review 2.  Potential of rescue and reactivation of tumor suppressor p53 for cancer therapy.

Authors:  Emi Hibino; Hidekazu Hiroaki
Journal:  Biophys Rev       Date:  2022-01-11

3.  Hesperidin Inhibits the p53-MDMXInteraction-Induced Apoptosis of Non-Small-Cell Lung Cancer and Enhances the Antitumor Effect of Carboplatin.

Authors:  Yu Feng; Hongjie Huo; Qiong Tang
Journal:  J Oncol       Date:  2022-09-16       Impact factor: 4.501

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.